Business Context and Reporting Period
This Form 8-K is a current report filed by Nukkleus Inc. (not T3 Defense Inc.) on November 19, 2024, regarding events occurring on November 8, 2024. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Jersey City, New Jersey. Its common stock (NUKK) and warrants (NUKKW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing reports a specific capital raise event rather than comprehensive financial statements. Key metrics disclosed include:
- Shares Sold: 138,556 shares of common stock.
- Purchase Price: $1.7765 per share.
- Aggregate Gross Proceeds: $246,145.
- Investor Type: Single accredited investor (NUKK TRACKER NOTES - CH1108678926 / 23714, series of notes (Series 24) issued by ProETPDAC).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The material change reported is the unregistered sale of equity securities under Item 3.02. The company sold 138,556 shares to an accredited investor relying on exemptions under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D. No advertising or general solicitation was employed, and the shares are subject to transfer restrictions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure regarding the unregistered nature of the sale and the reliance on specific regulatory exemptions. The transaction was executed via a Securities Purchase Agreement dated November 19, 2024.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (T3 Defense Inc.) and the actual registrant (Nukkleus Inc.).
- Confirm the identity of the accredited investor (NUKK TRACKER NOTES) and the nature of the "Series 24" notes.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the newly issued shares.
- Check subsequent filings for the impact of these proceeds on the company's overall cash position and dilution metrics.